Scancell Holdings (SCLP) Corporate presentation summary

Investment highlights and pipeline

• Lead asset iSCIB1+ is a novel, phase 3-ready DNA therapeutic vaccine for melanoma, showing 77% PFS at 22 months versus 43% for standard of care in an ongoing phase 2b trial, with a favorable safety profile and a defined regulatory path for global phase 3 with accelerated approval potential.

• The pipeline includes ImmunoBody® for hard-to-treat tumors, Moditope off-the-shelf peptide vaccines, and GlyMab Therapeutics, which develops high-affinity antibodies, with two partnered with Genmab.

• Multiple near-term catalysts include phase 3 initiation of iSCIB1+ in H2 2026, additional phase 2 data in H1 2027, and phase 2 initiation in neoadjuvant/adjuvant melanoma in H1 2027.

Clinical data and efficacy

• iSCIB1+ demonstrated compelling clinical benefit in advanced melanoma, with 62% ORR and 81% DCR, and 77% PFS at 22 months in phase 2b, outperforming standard checkpoint inhibitor regimens.

• Strong anti-tumor T cell responses correlated with clinical outcomes, with 94% of patients generating T-cell responses to iSCIB1+ peptides.

• Safety profile is favorable, with no increase in checkpoint inhibitor-related toxicities and manageable adverse events.

Regulatory and development milestones

• IND clearance for phase 3 trial received in January 2026, FDA fast track designation in April 2026, and regulatory submissions ongoing in the UK, EU, Canada, and Australia.

• Phase 3 trial initiation planned for H2 2026, with primary PFS readout in H2 2028 and potential for accelerated approval.

• Phase 2 in neoadjuvant/adjuvant melanoma expected to start in H1 2027.